Why did GAAP EPS rise so sharply from $0.29 to $1.02?

The prior-year quarter included roughly $0.38 per share of amortization of acquisition-related inventory step-up (about $231 million, tied to the NI acquisition), roughly $0.12 of restructuring and related costs, and about $0.17 of acquisition-related fees. Those charges were largely absent in the current quarter. Current-quarter GAAP EPS still benefited from lower intangibles amortization ($229 million versus $274 million in cost of sales and other deductions, combined in the reconciliation) and a $0.31 per-share amortization charge. Adjusted EPS, which excludes these items, grew a more representative 13%.

How is the business performing on an underlying basis?

Underlying sales grew 2% and underlying orders grew 1%. Growth was led by Final Control (+5%), Measurement & Analytical (+4%), AspenTech (+18%), and Control Systems & Software (+3%). Test & Measurement (-5%), Discrete Automation (-4%), and Safety & Productivity (-3%) declined. Management expects a second-half recovery in discrete markets, and its Q2 guidance of 1% to 2% underlying sales growth implies only modest near-term acceleration.

What are the key risks and open items for investors?

The main open items are the announced portfolio transactions involving AspenTech and Safety & Productivity, which are excluded from the 2025 guidance framework; investors will need updated guidance once these close or are finalized. Discrete markets remain weak, and the expected second-half recovery is not yet visible in orders. Net sales growth on a reported basis is guided at only 1.5% to 3.5% for FY2025, versus 3% to 5% underlying, indicating roughly 1.5 points of currency headwind. The filing's forward-looking statements also flag tariffs, currency, Russia-Ukraine and other conflicts, and cybersecurity risks.

How strong is Emerson's balance sheet and capital return program?

Cash and equivalents fell to $2.83 billion from $3.59 billion at September 30, 2024, largely due to $899 million of share repurchases, $301 million of dividends, and $98 million of currency effects. Short-term borrowings and current debt rose to $1.07 billion from $532 million, while long-term debt declined to $6.56 billion from $7.16 billion. Total equity fell to $26.4 billion. Management plans to return about $3.2 billion to shareholders in 2025 ($2.0 billion in buybacks and $1.2 billion in dividends), which is supported by guided free cash flow of $3.2 to $3.3 billion.

EMR 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 5, 2025. Cited figures are marked; the original filing is the authoritative source.

Emerson's fiscal Q1 2025 (quarter ended December 31, 2024) showed modest top-line growth with strong profit and cash conversion.

Net sales rose 1% to $4,175 million^a, and underlying sales grew 2%. Underlying orders grew 1%. Adjusted segment EBITA margin expanded 340 bps to 28.0%, and adjusted EPS rose 13% to $1.38, ahead of management's expectations for incremental margins and EPS.

Free cash flow nearly doubled to $694 million^b from $367 million. GAAP EPS of $1.02 versus $0.29 is not a like-for-like improvement, because the prior-year quarter absorbed about $0.38 of acquisition-related inventory step-up and about $0.12 of restructuring costs. The GAAP comparison is also distorted by AspenTech consolidation and lower amortization.

Management reiterated its full-year 2025 underlying sales growth guidance of 3% to 5% and its adjusted EPS guidance of $5.85 to $6.05^c, and it expects free cash flow of $3.2 to $3.3 billion. Its Q2 outlook calls for underlying sales growth of 1% to 2% and adjusted EPS of $1.38 to $1.42. Management attributed the outlook to resilient process and hybrid end markets and an expected second-half recovery in discrete markets.

Guidance excludes recently announced portfolio transactions involving AspenTech and Safety & Productivity, which are an important variable for investors to track. Capital returns are also significant, with about $3.2 billion^d planned for 2025, including $2.0 billion of buybacks and $1.2 billion of dividends. In the quarter, Emerson repurchased $899 million of stock and cash declined to $2.8 billion, while total debt rose to about $7.6 billion from $7.7 billion.

02—Key points

Key Highlights

Adjusted EPS grew 13% to $1.38 from $1.22, and management said results exceeded its expectations for incremental operating margins and EPS.
Adjusted segment EBITA margin expanded 340 bps to 28.0%, with Software and Control margins rising to 31.6% and Intelligent Devices to 26.1%.
Free cash flow nearly doubled to $694 million from $367 million, and operating cash flow rose 75% to $777 million.
Underlying sales grew 2% (reported 1%), with Final Control up 5% underlying and Test & Measurement down 5%; Discrete Automation remained weak at -4% underlying.
GAAP EPS of $1.02 versus $0.29 is inflated by the prior-year acquisition inventory step-up and restructuring charges; the GAAP comparison is not a clean measure of underlying improvement.
FY2025 guidance was reiterated: underlying sales growth of 3% to 5%, adjusted EPS of $5.85 to $6.05, and free cash flow of $3.2 to $3.3 billion, excluding pending AspenTech and Safety & Productivity transactions.
The Board declared a quarterly dividend of $0.5275 per share, and the company repurchased $899 million of stock in the quarter, with about $2.0 billion of buybacks planned for 2025.

03—Questions

Frequently Asked Questions

Why did GAAP EPS rise so sharply from $0.29 to $1.02?
The prior-year quarter included roughly $0.38 per share of amortization of acquisition-related inventory step-up (about $231 million, tied to the NI acquisition), roughly $0.12 of restructuring and related costs, and about $0.17 of acquisition-related fees. Those charges were largely absent in the current quarter. Current-quarter GAAP EPS still benefited from lower intangibles amortization ($229 million versus $274 million in cost of sales and other deductions, combined in the reconciliation) and a $0.31 per-share amortization charge. Adjusted EPS, which excludes these items, grew a more representative 13%.
How is the business performing on an underlying basis?
Underlying sales grew 2% and underlying orders grew 1%. Growth was led by Final Control (+5%), Measurement & Analytical (+4%), AspenTech (+18%), and Control Systems & Software (+3%). Test & Measurement (-5%), Discrete Automation (-4%), and Safety & Productivity (-3%) declined. Management expects a second-half recovery in discrete markets, and its Q2 guidance of 1% to 2% underlying sales growth implies only modest near-term acceleration.
What are the key risks and open items for investors?
The main open items are the announced portfolio transactions involving AspenTech and Safety & Productivity, which are excluded from the 2025 guidance framework; investors will need updated guidance once these close or are finalized. Discrete markets remain weak, and the expected second-half recovery is not yet visible in orders. Net sales growth on a reported basis is guided at only 1.5% to 3.5% for FY2025, versus 3% to 5% underlying, indicating roughly 1.5 points of currency headwind. The filing's forward-looking statements also flag tariffs, currency, Russia-Ukraine and other conflicts, and cybersecurity risks.
How strong is Emerson's balance sheet and capital return program?
Cash and equivalents fell to $2.83 billion from $3.59 billion at September 30, 2024, largely due to $899 million of share repurchases, $301 million of dividends, and $98 million of currency effects. Short-term borrowings and current debt rose to $1.07 billion from $532 million, while long-term debt declined to $6.56 billion from $7.16 billion. Total equity fell to $26.4 billion. Management plans to return about $3.2 billion to shareholders in 2025 ($2.0 billion in buybacks and $1.2 billion in dividends), which is supported by guided free cash flow of $3.2 to $3.3 billion.

04—Continue

← View all 8-K filings